Theravance Biopharma (TBPH) Depreciation & Amortization (CF) (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Depreciation & Amortization (CF) of $381000.0 for Q1 2026, down 7.75% year-over-year from $413000.0 in Q1 2025, and down 4.51% quarter-over-quarter from $399000.0 in Q4 2025.
Theravance Biopharma (TBPH) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Depreciation & Amortization (CF) for 14 consecutive years, with $381000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 7.75% year-over-year to $381000.0; the TTM figure through Mar 2026 stood at $1.6 million (down 5.74% YoY), while the FY2025 annual figure was $1.6 million, down 4.91% from the prior year.
- Depreciation & Amortization (CF) declined to $381000.0 in Q1 2026 per TBPH's latest filing, from $399000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.1 million in Q3 2022 and bottomed at $381000.0 in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $554941.2 across 5 years, with a median of $429000.0 in 2024.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) soared 162.55% — and 2023, when it slumped 61.01%.
- Theravance Biopharma's Depreciation & Amortization (CF) stood at $659000.0 in 2022, then sank by 40.52% to $392000.0 in 2023, then climbed by 7.65% to $422000.0 in 2024, then dropped by 5.45% to $399000.0 in 2025, then dropped by 4.51% to $381000.0 in 2026.
- Business Quant data shows TBPH's Depreciation & Amortization (CF) at $381000.0 in Q1 2026, $399000.0 in Q4 2025, and $405000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 367,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 367,000.00 |
| Jun 30, 2026 | 367,000.00 |
| Mar 31, 2026 | 381,000.00 |
| Mar 31, 2026 | 381,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Dec 31, 2025 | 399,000.00 |
| Sep 30, 2025 | 405,000.00 |
| Sep 30, 2025 | 405,000.00 |
| Jun 30, 2025 | 409,000.00 |
| Jun 30, 2025 | 409,000.00 |
| Mar 31, 2025 | 413,000.00 |
| Mar 31, 2025 | 413,000.00 |
| Dec 31, 2024 | 422,000.00 |
| Dec 31, 2024 | 422,000.00 |
| Sep 30, 2024 | 429,000.00 |
| Sep 30, 2024 | 429,000.00 |
| Jun 30, 2024 | 427,000.00 |
| Jun 30, 2024 | 427,000.00 |
| Mar 31, 2024 | 432,000.00 |
| Mar 31, 2024 | 432,000.00 |